Get the Daily Brief
Latest Biotech News
Lilly’s Asia push: Grabody and LEAD pacts... $3.8B in platform bets
Eli Lilly struck major collaborations in Asia, licensing ABL Bio’s Grabody bispecific platform in a deal valued at up to $2.6 billion and signing a $1.2 billion research pact with SanegeneBio to...
CRISPR wheat triggers nitrogen fixation – UC Davis engineers crops to recruit soil bacteria
Researchers at UC Davis used CRISPR engineering to boost a plant metabolite in wheat that encourages soil bacteria to form biofilms and fix atmospheric nitrogen, reducing the need for synthetic...
Bayer’s asundexian cuts stroke risk – Phase 3 revives FXIa class
Bayer reported a late-stage (Phase 3) trial showing its oral factor XIa inhibitor asundexian reduced the risk of recurrent stroke in a subset of patients. The readout, disclosed by Bayer,...
Novo Nordisk’s semaglutide misses in Alzheimer’s – Two trials fail to slow progression
Novo Nordisk announced that semaglutide, a GLP‑1 receptor agonist, failed to delay disease progression in two closely watched Alzheimer’s trials. The company said neither study met the primary...
Eli Lilly doubles down on bispecifics and RNAi: $3.8B in Asia deals
Eli Lilly signed two major partnerships in Asia that together carry roughly $3.8 billion in potential value. Lilly granted ABL Bio rights to its Grabody platform in a licensing and research...
Biogen pays $50M upfront to Dayra – Oral macrocycles deal in I&I
Biogen committed a $50 million upfront payment to Dayra Therapeutics in a collaboration to develop oral macrocycles for immune and inflammatory (I&I) diseases. The deal, announced by Biogen and...
Carolyn Bertozzi returns to Lilly board – Nobel laureate to rejoin Dec. 8
Eli Lilly disclosed in an SEC filing that Nobel laureate Carolyn Bertozzi will rejoin the company’s board of directors on Dec. 8. Bertozzi, who won the 2022 Nobel Prize in Chemistry, brings...
Blood four‑gene signature rules out bacterial LRTI – Nature Communications validation
Researchers published a four‑gene blood signature in Nature Communications that accurately excludes bacterial causes of lower respiratory tract infections (LRTIs). The study validated the minimal...
Blood biomarkers map Alzheimer’s across cognitive stages – Accessible disease tracking
A study published in Nature Communications identified blood biomarkers that track cognitive decline across Alzheimer’s disease stages in a community‑based population. The investigators correlated...
Giant bacteriophage targets drug‑resistant Pseudomonas – Phage therapy renewed
An international research team described a giant bacteriophage that effectively attacks metallo‑β‑lactamase producing strains of Pseudomonas aeruginosa, a pathogen notorious for multidrug...
Automated MRI flags clinically significant prostate cancer – AI system validated
Researchers published a Nature Communications study introducing an automated MRI system designed to detect clinically significant prostate cancer with high reliability. The AI‑driven pipeline...
Craig Crews and Mikael Dolsten raise $32M for Quarry Thera – New biotech funds launch
A new biotech, Quarry Thera, secured $32 million in seed funding led by industry veterans Craig Crews and Mikael Dolsten, according to the company announcement. The round brings prominent...
Avadel takeover duel: Lundbeck bids, Alkermes counters
Avadel Pharmaceuticals became the center of an active bidding contest after Lundbeck emerged with a counteroffer to Alkermes’ proposed acquisition. Avadel’s board declared Lundbeck’s proposal a...
Bertozzi returns to Lilly board: Nobel laureate to rejoin Dec. 8
Eli Lilly disclosed in an SEC filing that Nobel laureate Carolyn Bertozzi will rejoin its board on Dec. 8. Bertozzi, awarded the 2022 Nobel Prize in Chemistry, brings expertise in glycobiology and...
Semaglutide slows CKD progression in diabetics — study
A multicenter study reported that semaglutide significantly slowed kidney disease progression in patients with type 2 diabetes and chronic kidney disease. Investigators led by Alemu, Narasimhan,...
ASAH1-linked sphingolipid pathway fuels venetoclax resistance in AML
Researchers disclosed that altered sphingolipid metabolism driven by ASAH1 contributes to venetoclax resistance in acute myeloid leukemia, particularly in monocytic phenotypes. The BMC Cancer...
Immune atlas pins CD4 memory program to type 1 diabetes
A joint human-and-mouse profiling study published in Science Immunology identified a conserved CD4+ memory T‑cell transcriptional and epigenetic program associated with type 1 diabetes....
APOE4 meets CRISPR — gene editing and blood biomarkers reshape Alzheimer’s strategy
Two major Alzheimer’s research updates surfaced: one review argued that CRISPR-based editing of APOE4 alleles could reduce genetic risk, and a Nature Communications study reported blood biomarkers...
Multiple myeloma: exosomes and complement signals reshape treatment response
Two translational studies revealed mechanisms that may modulate multiple myeloma therapy. One paper showed tumor‑derived exosomes influence bortezomib response via redox pathways and identified...
Two preclinical TNBC approaches: venom peptide targets PD‑L1 and gallium photosensitizers advance PDT
Researchers reported two independent preclinical advances against triple-negative breast cancer (TNBC). One team characterized MP‑1, a wasp‑venom derived peptide that binds PD‑L1 and showed target...